IXEMPRA® (Ixabepilone), a microtubulin inhibitor in Phase 2 development for the European market for metastatic breast cancer
IXEMPRA® is a small molecule targeted inhibitor of microtubules. It was exclusively in-licensed from R-PHARM U.S. for development in Europe. This drug was originally developed by Bristol Myers Squibb and is approved for metastatic breast cancer patients in the U.S.
Allarity is currently conducting a DRP®-guided Phase 2 clinical trial to evaluate IXEMPRA® for the treatment of third-line metastatic breast cancer, with numerous trial sites planned in Europe, including Belgium, England, Denmark, Finland, Poland and Germany. The Company’s protocol plans for an enrollment target of 60 IXEMPRA® DRP®-selected patients. By using DRP® for patient selection, Allarity aims to provide a superior clinical benefit to patients receiving IXEMPRA®, as compared to historical clinical data from breast cancer patients treated with IXEMPRA® but not selected with DRP®. The enrollment of the first patient was announced on March 4, 2021.
The IXEMPRA® DRP is validated in metastatic breast cancer.
Ixempra® (ixabepilone) is a cell-cycle specific antimicrotubule agent. It attaches to a section of the microtubule and acts on the structure and function of the cell, ultimately causing cell death. Ixempra® seeks to block the ability of cells to modify the internal ‘skeleton’ that they need to divide and multiply. When the skeleton is unable to change, the cancer cells cannot divide and eventually die. Both cancer cells and non-cancer cells, such as nerve cells, are affected by Ixempra®, which could lead to side effects.